Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study

NCT02268890 is registered in ClinicalTrials.gov with Johnson & Johnson Taiwan Ltd as lead sponsor.

NCT NCT02268890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02268890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study
Lead sponsor
Johnson & Johnson Taiwan Ltd
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2014
Completion date
July 31, 2015
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma